Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.

Halford, Sarah; Wan, Susan; Dragoni, Ilaria; Silvester, Julie; Nazarov, Bobojon; Anthony, Daniel; Anthony, Suzie; Ladds, Emma; Norrie, John; Dhaliwal, Kevin

Halford, Sarah; Wan, Susan; Dragoni, Ilaria; Silvester, Julie; Nazarov, Bobojon; Anthony, Daniel; Anthony, Suzie; Ladds, Emma; Norrie, John; Dhaliwal, Kevin.

Afiliación

Halford S; Cancer Research UK Centre for Drug Development, London, UK. sarah.halford@cancer.org.uk.
Wan S; Cancer Research UK Centre for Drug Development, London, UK.
Dragoni I; Cancer Research UK Centre for Drug Development, London, UK.
Silvester J; Cancer Research UK Centre for Drug Development, London, UK.
Nazarov B; Latus Therapeutics, London, UK.
Anthony D; University of Oxford, Oxford, UK.
Anthony S; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Ladds E; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Norrie J; The University of Edinburgh, Edinburgh, UK.
Dhaliwal K; The University of Edinburgh, Edinburgh, UK.

Trials ; 23(1): 336, 2022 Apr 21.

Article en En | MEDLINE | ID: mdl-35449061

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google